Biotechnology News and Research

RSS

Atherotech to showcase VAP Cholesterol Test at Internal Medicine 2010

Atherotech Inc. announced it will exhibit its VAP® Cholesterol Test in booth #1305 at Internal Medicine 2010, the annual scientific meeting of the American College of Physicians (ACP). The meeting takes place April 22-24, 2010, at the Metro Toronto Convention Centre in Toronto, Canada.

20 Apr 2010

Encorium Group reports 21.4% decrease in fourth-quarter net revenue

Encorium Group, Inc., a full service multinational clinical research organization conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced its financial results for the fourth quarter and year ended December 31, 2009.

20 Apr 2010

Array BioPharma signs agreement with Novartis for worldwide development of ARRY-162

Array BioPharma Inc. today announced that it has entered into an agreement with Novartis for the worldwide development of the small-molecule MEK inhibitors ARRY-162, currently in a Phase 1 cancer trial, its back-up, ARRY-300, and other MEK inhibitors.

20 Apr 2010

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced updated overall survival findings from a phase I/II study of nab®-paclitaxel (ABRAXANE® for Injectable Suspension) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with gemcitabine, demonstrated increased survival of the first-line treatment of patients with advanced pancreatic cancer.

19 Apr 2010

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has established an action plan for obtaining cost reimbursement coverage for Generex Oal-lyn™, including the development of an insurance product that covers the costs of Generex Oral-lyn™ and any additional and/or comparable diabetes products.

19 Apr 2010

NanoImaging Services receives grant to develop methods for characterization of nanoparticle morphology

NanoImaging Services, Inc., announced today that it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health through the National Center for Research Resources to develop new methods for quantitative characterization of nanoparticle morphology and aggregation state using transmission electron microscopy. The grant provides approximately $200,000 in research and development funds for a Phase I study.

19 Apr 2010

Dyadic International announces agreement to resolve consolidated stockholder class action lawsuit

Dyadic International, Inc. announced today an agreement to resolve the consolidated stockholder class action lawsuit against Dyadic and certain of its current and former officers and directors which was initially filed in October 2007.

19 Apr 2010

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

Myriad Pharmaceuticals, Inc. today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with Javelin Pharmaceuticals.

19 Apr 2010

Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010. The Company reported total revenue of $174.1 million for the quarter ended March 31, 2010, which includes net product sales of $172.3 million. Non-GAAP operating loss was $3.8 million for the quarter ended March 31, 2010, compared to $19.9 million for the same period in 2009.

19 Apr 2010

Investment report on Generex Biotechnology from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Generex Biotechnology Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

19 Apr 2010

First US implant of Interventional Spine's RENEW Interspinous Allograft Technology for LSS

Interventional Spine, Inc. today announced the first commercial implant in the United States of its RENEW™ Interspinous Allograft Technology for the Treatment of Lumbar Spinal Stenosis (LSS).

19 Apr 2010

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.

19 Apr 2010

Stallergenes' US phase III clinical trial of Oralair achieves primary endpoint

Stallergenes S.A. today announced the first results of a phase III clinical trial (VO61.08) conducted in the USA on its sublingual grass pollen immunotherapy tablet, Oralair(R).

19 Apr 2010

New p53 knockout rat model improves timelines for carcinogenicity screening

Sigma Life Science, the innovative biological products and services brand of Sigma-Aldrich, today introduced the world's first p53 'knockout' rat model, an important development that is expected to, due to the rat's closer physiological and metabolic similarity to humans, significantly improve timelines for carcinogenicity screening and reduce time to market for therapeutics.

19 Apr 2010

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.

19 Apr 2010

Cell Therapeutics receives feedback regarding proposed filing of MAA for pixantrone

Cell Therapeutics, Inc. today announced that it met with and received feedback from the rapporteurs and the European Medicines Agency's medical reviewers regarding a proposed filing of a Marketing Authorization Application for pixantrone in the European Union to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.

19 Apr 2010

Budget impact of traditional fecal management methods to be presented at SAWC/WHS 2010

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new study results that demonstrate hospitals could realize substantial savings by substituting Flexi-Seal FMS for traditional fecal management methods.

19 Apr 2010

MedImmune to present ten abstracts at American Association for Cancer Research meeting

MedImmune today announced that ten abstracts on progress being made in various oncology programs will be presented during the Annual Meeting of the American Association for Cancer Research in Washington, DC from April 17 to 21.

17 Apr 2010

BIO selects Congresswoman Anna Eshoo as Legislator of the Year

The Biotechnology Industry Organization (BIO) announced today its selection of Congresswoman Anna Eshoo (D-CA) as Legislator of the Year for 2009-2010. Representative Eshoo received the award as part of the BIO Legislative Day Fly-In earlier this week.

17 Apr 2010

Access to NAbs testing important for MS therapy management

Teva Neuroscience today announced results at the 62nd American Academy of Neurology Annual Meeting which demonstrated that eliminating barriers to neutralizing antibodies (NAbs) testing significantly impacted multiple sclerosis (MS) treatment choices in patients receiving interferon beta (IFNβ) therapies.

17 Apr 2010

Biotechnology News and Research

Atherotech to showcase VAP Cholesterol Test at Internal Medicine 2010

Encorium Group reports 21.4% decrease in fourth-quarter net revenue

Array BioPharma signs agreement with Novartis for worldwide development of ARRY-162

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

NanoImaging Services receives grant to develop methods for characterization of nanoparticle morphology

Dyadic International announces agreement to resolve consolidated stockholder class action lawsuit

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010

Investment report on Generex Biotechnology from MicroStockProfit.com

First US implant of Interventional Spine's RENEW Interspinous Allograft Technology for LSS

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

Stallergenes' US phase III clinical trial of Oralair achieves primary endpoint

New p53 knockout rat model improves timelines for carcinogenicity screening

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Cell Therapeutics receives feedback regarding proposed filing of MAA for pixantrone

Budget impact of traditional fecal management methods to be presented at SAWC/WHS 2010

MedImmune to present ten abstracts at American Association for Cancer Research meeting

BIO selects Congresswoman Anna Eshoo as Legislator of the Year

Access to NAbs testing important for MS therapy management

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News